US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is ...

US health officials have issued a warning linking RSV vaccines to an increased risk of a serious neurological condition. The ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

In the US Food and Drug Administration (FDA) study, officials combed through vaccine reaction data on two RSV jabs, called Abrysvo and Arexvy, documented between May 2023 and July last year.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is already noted as a potential complication in patient information.

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.

The suits allege that nanoparticles used in Moderna's Spikevax COVID-19 shot and recently approved mResvia vaccine for RSV – which competes with GSK's $1.7 billion blockbuster Arexvy ...